Mesoblast climbs on FDA support for heart failure drug approval

Mesoblast

11/03/2024 15:40

** U.S.-listed shares of Australia-based drug developer
Mesoblast  MSB.AX   MESO.O  rise 28.8% to $2.79, its highest
level in over six months 
    ** Co late on Sunday said the U.S. FDA supported an
accelerated approval pathway for its heart failure drug,
rexlemestrocel-L
    ** Rexlemestrocel-L is in development for advanced chronic
heart failure and chronic low back pain
     ** Co to request a meeting with the FDA to discuss data
presentation and FDA expectations to file for accelerated
approval for the drug 
    ** Including session moves, stock has fallen 56.8% in the
last 12 months 

 (Reporting by Sneha  S K)
 ((Sneha.SK@thomsonreuters.com;))